Hypoxia-activated Neuropeptide Y/Y5 Receptor/RhoA Pathway Triggers Chromosomal Instability and Bone Metastasis in Ewing Sarcoma
Overview
Authors
Affiliations
Adverse prognosis in Ewing sarcoma (ES) is associated with the presence of metastases, particularly in bone, tumor hypoxia and chromosomal instability (CIN). Yet, a mechanistic link between these factors remains unknown. We demonstrate that in ES, tumor hypoxia selectively exacerbates bone metastasis. This process is triggered by hypoxia-induced stimulation of the neuropeptide Y (NPY)/Y5 receptor (Y5R) pathway, which leads to RhoA over-activation and cytokinesis failure. These mitotic defects result in the formation of polyploid ES cells, the progeny of which exhibit high CIN, an ability to invade and colonize bone, and a resistance to chemotherapy. Blocking Y5R in hypoxic ES tumors prevents polyploidization and bone metastasis. Our findings provide evidence for the role of the hypoxia-inducible NPY/Y5R/RhoA axis in promoting genomic changes and subsequent osseous dissemination in ES, and suggest that targeting this pathway may prevent CIN and disease progression in ES and other cancers rich in NPY and Y5R.
Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.
Chambers C, Watakul S, Schofield P, Howell A, Zhu J, Tran A Sci Adv. 2025; 11(11):eadq4416.
PMID: 40073121 PMC: 11900870. DOI: 10.1126/sciadv.adq4416.
Neuropeptide Y in cancer-biological functions and potential clinical implications.
Sigorski D, Sejda A, Abualsaud N, Krawczyk E, Izycka-Swieszewska E, Kitlinska J Cancer Metastasis Rev. 2025; 44(1):21.
PMID: 39760953 PMC: 11703900. DOI: 10.1007/s10555-024-10237-z.
A novel histone acetylation-associated gene signature with prognostic value in Ewing sarcoma.
Wu A, Liu F, Zhou L, Jiang R, Yu S, Zhou Z Discov Oncol. 2024; 15(1):848.
PMID: 39738986 PMC: 11685356. DOI: 10.1007/s12672-024-01689-4.
Ning Y, Zheng M, Zhang Y, Jiao Y, Wang J, Zhang S Cancer Cell Int. 2024; 24(1):339.
PMID: 39402585 PMC: 11475559. DOI: 10.1186/s12935-024-03519-7.
Lee P, Koseki L, Haitani T, Harada H, Kobayashi M Cancers (Basel). 2024; 16(9).
PMID: 38730681 PMC: 11083728. DOI: 10.3390/cancers16091729.